PAD Formulary : Surrey Heartlands
PAD - Prescribing Advisory Database
PLEASE NOTE : This is a development system.

For Surrey PAD, please go to https://surreyccg.res-systems.net/PAD.

You are here : Home > Latest Additions

Latest Additions

Records returned : 266 (on 22 Dec 2024 at 02:05:19).

Drug
Indication
Status
Trust Alignment
Links
Restrictions/Comments
01.03.05
Omeprazole
Acid Suppression (Children)
Green
Formulations :
  • Capsules
Primary Care
ASPH
RSFT
SASH
SABP
Guidelines BNF SPC
Important
Preferred
1st line option in children who are able to swallow capsules. Most capsules can also be opened and mixed with water or fruit juice (licensed).
07.04.01
Doxazosin
Benign prostatic hyperplasia
Green
Formulations :
  • Immediate release tablets
Primary Care
ASPH
RSFT
SASH
SABP
BNF SPC
Preferred
07.04.02
Tamsulosin hydrochloride
Benign prostatic hyperplasia
Green
Formulations :
  • Modified release capsules
Primary Care
ASPH
RSFT
SASH
SABP
BNF SPC
Preferred
07.04.02
Solifenacin
Overactive bladder (adults)
Green
Formulations :
  • Tablets
Primary Care
ASPH
RSFT
SASH
SABP
Guidelines BNF SPC
Important
Preferred
1st line unless contra-indicated
02.04.00
04.07.04
Propranolol hydrochloride
Migraine (prevention)
Green
Formulations :
  • Tablets
Primary Care
ASPH
RSFT
SASH
SABP
BNF SPC
04.07.04
04.08.01
Topiramate
Migraine (prevention)
Green
Formulations :
  • Tablets
Primary Care
ASPH
RSFT
SASH
SABP
BNF SPC
SA
Important
Pregnancy Prevention Plan required for females of childbearing potential.
04.03.01
04.07.03
04.07.04
Amitriptyline hydrochloride
Migraine (prevention)
Green
Formulations :
  • Oral solution
  • Tablets
Primary Care
ASPH
RSFT
SASH
SABP
BNF SPC
04.03.01
04.07.03
04.07.04
Pain (Neuropathic)
Green
Formulations :
  • Oral solution
  • Tablets
Primary Care
ASPH
RSFT
SASH
SABP
BNF SPC
Preferred
04.06.00
Domperidone
Nausea and vomiting (Parkinson's disease)
Green
Formulations :
  • Oral suspension
  • Tablets
Primary Care
ASPH
RSFT
SASH
SABP
BNF SPC
SA
Un
04.07.03
Duloxetine
Pain (Neuropathic)
Green
Formulations :
  • Capsules
Primary Care
ASPH
RSFT
SASH
SABP
BNF SPC
Un
Important
Licensed only for diabetic peripheral neuropathic pain but also recommended as per NICE CG173 (off- label indication) as a treatment option in neuropathic pain.
04.07.03
04.07.04
04.08.01
Gabapentin
Pain (Neuropathic)
Green
Formulations :
  • Capsules
  • Oral solution
  • Tablets
Primary Care
ASPH
RSFT
SASH
SABP
BNF NICE SPC
CD
NICE
Important
First line gabapentinoid.
01.03.05
Lansoprazole
Acid suppression (Adults)
Green
Formulations :
  • Capsules
Primary Care
ASPH
RSFT
SASH
SABP
Guidelines BNF SPC
Important
Preferred
1st line for patients with no swallowing difficulties. 2nd line for adults with swallowing difficulties / feeding tubes - capsules can be opened.
01.03.05
Omeprazole
Acid suppression (Adults)
Green
Formulations :
  • Capsules
Primary Care
ASPH
RSFT
SASH
SABP
Guidelines BNF SPC
Important
Preferred
1st line for patients with no swallowing difficulties.
03.04.03
Adrenaline/epinephrine
Anaphylaxis
Green
Formulations :
  • Auto-injector
Primary Care
ASPH
RSFT
SASH
SABP
BNF SPC
Important
Epipen,/Jext / Emerade - Prescribe by brand. Injection technique is device-specific
10.02.02
Pridinol
Spasticity and muscle spasm
Green
Formulations :
  • Not Specified
Primary Care
ASPH
RSFT
SASH
SABP
BNF SPC
U
10.03.02
Capsaicin
Osteoarthritis
Green
Formulations :
  • Cream
Primary Care
ASPH
RSFT
SASH
SABP
BNF SPC
Important
0.025% cream (Zacin brand) is licensed for this indication. (0.075% Axsain cream is NOT licensed for osteoarthritis)
06.04.02
Testosterone
Low sexual desire in menopausal women
Green
Formulations :
  • Gel
Primary Care
ASPH
RSFT
SASH
SABP
BNF SPC
Un
Important
Prescribe generically as "Testosterone 2% transdermal gel 60g"
06.01.02
Dapagliflozin
Chronic Kidney Disease
Green
Formulations :
  • Tablets
Primary Care
ASPH
RSFT
SASH
SABP
Guidelines BNF SPC
Important
If a patient with diabetes were on insulin and on multiple other treatments, a discussion with the specialist team may be prudent prior to dapagliflozin initiation.
09.06.04
Colecalciferol
Vitamin D deficiency and insufficiency
Green
Formulations :
  • Capsules
  • Tablets
Primary Care
ASPH
RSFT
SASH
SABP
Guidelines BNF SPC
Important
1,000iu tablets 50,000iu capsules
Resource ThickenUp Clear
Dysphagia
Green
Formulations :
  • Powder
Primary Care
ASPH
RSFT
SASH
SABP
Guidelines BNF SPC
Ropinirole
Restless Leg Syndrome
Green
Formulations :
  • Immediate release tablets
Primary Care
ASPH
RSFT
SASH
SABP
BNF SPC
Important
Preferred
Patients with severe symptoms, who are obese, co-morbid depression, increased risk of falls or cognitive impairment
02.05.05
04.07.04
Candesartan cilexetil
Migraine (prevention)
Green
Formulations :
  • Tablets
Primary Care
ASPH
RSFT
SASH
SABP
BNF SPC
Un
Important
Off-label use
06.01.01
Insulin glargine
Diabetes Mellitus
Green
Formulations :
  • Injection
Primary Care
ASPH
RSFT
SASH
SABP
Guidelines BNF SPC
05.01.07
Fidaxomicin
Clostridioides difficile
Green
Formulations :
  • Oral suspension
  • Tablets
Primary Care
ASPH
RSFT
SASH
SABP
BNF SPC
R
Important
Granules (for oral suspension) should be used in patients requiring a liquid preparation. Restricted Use - for use when indicated by local trust antimicrobial guidelines, NICE condensed summary table of antimicrobial guidance or specialist microbiology recommendation. For any patient requiring a liquid preparation, fidaxomicin granules should be prescribed. The APC notes that although current NICE guidelines recommend vancomycin first line, it is recognised that this was based on cost and in exceptional cases when a liquid is required, fidaxomicin granules are appropriate to prescribe as a licensed preparation that supports timely treatment.
01.03.01
Famotidine
Acid suppression (Adults)
Green
Formulations :
  • Tablets
Primary Care
ASPH
RSFT
SASH
SABP
Guidelines BNF SPC
Preferred
05.01.07
11.03.01
Vancomycin hydrochloride
Clostridioides difficile
Green
Formulations :
  • Capsules
Primary Care
ASPH
RSFT
SASH
SABP
BNF SPC
R
Important
Restricted Use - for use when indicated by local trust antimicrobial guidelines, NICE condensed summary table of antimicrobial guidance or specialist microbiology recommendation. The APC notes that although current NICE guidelines recommend vancomycin first line for treatment of C diff, it is recognised that this was based on cost and in exceptional cases when a liquid is required, fidaxomicin granules are appropriate to prescribe as a licensed preparation that supports timely treatment.
01.05.02
11.04.01
Prednisolone
Inflammatory bowel disease
Green
Formulations :
  • Tablets
Primary Care
ASPH
RSFT
SASH
SABP
Guidelines BNF SPC
Important
Tablets can be dispersed for immediate administration.
01.05.02
11.04.01
Inflammatory bowel disease
Green
Formulations :
  • Soluble tablets
Primary Care
ASPH
RSFT
SASH
SABP
Guidelines BNF SPC
R
Important
Paediatrics only at SASH. Paediatrics and oncology at ASPH
01.05.02
11.04.01
Inflammatory bowel disease
Green
Formulations :
  • Oral solution
Primary Care
ASPH
RSFT
SASH
SABP
Guidelines BNF SPC
R
Important
Paediatric doses and NG/NJ tube only
02.08.02
Rivaroxaban
Prevention of atherothrombotic events - coronary or peripheral artery disease
Green
Formulations :
  • Tablets
Primary Care
ASPH
RSFT
SASH
SABP
BNF NICE SPC
NICE
02.06.01
Isosorbide mononitrate
Angina
Green
Formulations :
  • Tablets
Primary Care
ASPH
RSFT
SASH
SABP
BNF SPC
Important
Preferred
Twice daily (assymetric) dosing is recommended
02.12.00
Icosapent
Lipid modification
Green
Formulations :
  • Capsules
Primary Care
ASPH
RSFT
SASH
SABP
Guidelines BNF NICE SPC
NICE
Important
With statin therapy in patients with raised triglycerides
02.12.00
Inclisiran
Lipid modification
Green
Formulations :
  • Subcutaneous injection (sc)
Primary Care
ASPH
RSFT
SASH
SABP
Guidelines BNF NICE SPC
NICE
Important
Prescribing in secondary care is commissioned by NHSE - Blueteq forms are required.
03.04.03
Adrenaline/epinephrine
Anaphylaxis
Green
Formulations :
  • Injection
Primary Care
ASPH
RSFT
SASH
SABP
BNF SPC
Important
Ampoules and pre-filled syringes. 1:1,000 and 1:10,000
03.03.02
Montelukast
Asthma
Green
Formulations :
  • Chewable tablets
  • Sachets (granules)
  • Tablets
Primary Care
ASPH
RSFT
SASH
SABP
Guidelines BNF SPC
SA
Important
https://www.gov.uk/drug-safety-update/montelukast-singulair-reminder-of-the-risk-of-neuropsychiatric-reactions
09.01.01
Ferric maltol
Iron-deficiency anaemia
Green (see narrative)
Formulations :
  • Capsules
Primary Care
ASPH
RSFT
SASH
SABP
BNF SPC
02.06.01
Isosorbide mononitrate
Angina
Green (see narrative)
Formulations :
  • Modified release capsules
  • Modified release tablets
Primary Care
ASPH
RSFT
SASH
SABP
BNF SPC
Important
Restricted to when isosorbide mononitrate standard release is not suitable. Primary Care prescribers should follow local advice on the most cost-effective brands. OptimiseRx will be used to identify current recommendations.
01.06.06
Naloxegol
Constipation
Green (see narrative)
Formulations :
  • Tablets
Primary Care
ASPH
RSFT
SASH
SABP
Guidelines BNF SPC
Important
Opioid-induced constipation. Only after other laxatives have been unsuccessful.
01.03.05
Lansoprazole
Acid Suppression (Children)
Green (see narrative)
Formulations :
  • Capsules
Primary Care
ASPH
RSFT
SASH
SABP
Guidelines BNF SPC
Important
2nd line treatment option in children who are able to swallow capsules. Some capsules are licensed to be opened and have their contents mixed with water, apple/tomato juice or sprinkled on soft food (e.g. yoghurt, apple puree)
01.03.05
Acid Suppression (Children)
Green (see narrative)
Formulations :
  • Oro-dispersible
Primary Care
ASPH
RSFT
SASH
SABP
Guidelines BNF SPC
Important
2nd line treatment option in children unable to swallow omeprazole or lansoprazole capsules. Oro-dispersible tablets disperse in the mouth to release gastro-resistant granules. Lansoprazole is NOT absorbed sublingually. The gastro-resistant granules must be swallowed for the medicine to be effective. The FasTabs® can also be administered in apple or orange juice.
01.03.05
Esomeprazole
Acid Suppression (Children)
Green (see narrative)
Formulations :
  • Granules
Primary Care
ASPH
RSFT
SASH
SABP
Guidelines BNF SPC
Important
Branded Nexium granules for children/infants with enteral feeding tubes (6Fr or larger). Off-label use in infants under 1 year. Generic granules 3rd line in children/infants under 1 year without an NG tube. Refer to PPI algorithm for details.
01.03.01
Nizatidine
Acid suppression (Adults)
Green (see narrative)
Formulations :
  • Capsules
Primary Care
ASPH
RSFT
SASH
SABP
Guidelines BNF SPC
Important
Preferred
For use where a PPI is not suitable and an H2RA is indicated. For doses of 300mg, please prescribe 2x150mg as this is considerably more cost effective.
01.03.01
Cimetidine
Acid suppression (Adults)
Green (see narrative)
Formulations :
  • Oral solution
  • Tablets
Primary Care
ASPH
RSFT
SASH
SABP
Guidelines BNF SPC
R
Important
Reserve for use where a PPI AND and other H2RAs are not suitable OR where a liquid preparation is required. Check for drug interactions.
04.07.02
Morphine sulfate
Pain
Green (see narrative)
Formulations :
  • Capsules (slow release)
  • Granules (slow release)
  • Tablets (slow release)
Primary Care
ASPH
RSFT
SASH
SABP
Guidelines BNF SPC
CD
Important
Prescribe modified-release preparations by brand - refer to local guidelines for preferred brands. Zomorph capsules (12-hourly) can be opened for administration in patients unable to swallow the capsules.
04.07.02
Oxycodone
Pain
Green (see narrative)
Formulations :
  • Modified release tablets
Primary Care
ASPH
RSFT
SASH
SABP
Guidelines BNF SPC
CD
Important
For use in patients where morphine sulfate is not suitable / not tolerated. Modified-release preparations to be prescribed by brand
04.07.02
Tramadol hydrochloride
Pain
Green (see narrative)
Formulations :
  • Modified release capsules
  • Modified release tablets
Primary Care
ASPH
RSFT
SASH
SABP
Guidelines BNF SPC
CD
SA
Important
Branded prescribing is recommended for modified release tramadol. Do not confuse 12 hourly and 24 hourly preparations. Consider tramadol where maximum tolerated doses of codeine / dihydrocodeine are ineffective.
04.07.02
Pain
Green (see narrative)
Formulations :
  • Soluble tablets
Primary Care
ASPH
RSFT
SASH
SABP
Guidelines BNF SPC
CD
Important
Reserved for patients unable to swallow solid dose forms or for administration via an enteral tube. Consider use where maximum tolerated doses of codeine / dihydrocodeine are ineffective.
04.07.02
Pain
Green (see narrative)
Formulations :
  • Oro-dispersible
Primary Care
ASPH
RSFT
SASH
SABP
Guidelines BNF SPC
CD
Important
Reserved for patients unable to swallow solid dose forms or for administration via an enteral tube. Consider use where maximum tolerated doses of codeine / dihydrocodeine are ineffective.
01.03.05
Esomeprazole
Acid suppression (Adults)
Green (see narrative)
Formulations :
  • Capsules
Primary Care
ASPH
RSFT
SASH
SABP
Guidelines BNF SPC
Important
Lansoprazole capsules are the preferred option. Esomeprazole 40mg restricted to short-term use or for Zollinger-Ellison syndrome.
01.03.05
Acid suppression (Adults)
Green (see narrative)
Formulations :
  • Granules
Primary Care
ASPH
RSFT
SASH
SABP
Guidelines BNF SPC
Important
Lansoprazole oro-dispersible 1st-line. Esomeprazole is 3rd-line. Restricted to patients with swallowing difficulties or with large bore enteral feeding tube when other options are not clinically appropriate. Do not use in tubes less than 6F.
10.03.02
Capsaicin
Pain (Neuropathic)
Green (see narrative)
Formulations :
  • Cream
Primary Care
ASPH
RSFT
SASH
SABP
BNF NICE SPC
NICE
Important
For patients with localised neuropathic pain who cannot tolerate / wish to avoid oral treatments (amitriptyline or duloxetine)
0.075% cream (Axsain brand) is licensed for this indication
04.07.03
04.07.04
04.08.01
Pregabalin
Pain (Neuropathic)
Green (see narrative)
Formulations :
  • Oral solution
Primary Care
ASPH
RSFT
SASH
SABP
BNF SPC
CD
04.07.02
Tramadol hydrochloride
Pain (Neuropathic)
Green (see narrative)
Formulations :
  • Capsules
  • Soluble tablets
Primary Care
ASPH
RSFT
SASH
SABP
BNF SPC
CD
Important
NICE CG 173 Consider tramadol only if acute rescue therapy is needed. Prescribe a short course (2-4 weeks on an acute script) and review at least every 3 months.
04.07.02
Pain (Neuropathic)
Green (see narrative)
Formulations :
  • Modified release capsules
  • Modified release tablets
Primary Care
ASPH
RSFT
SASH
SABP
BNF SPC
CD
Important
NICE CG 173 Consider tramadol only if acute rescue therapy is needed. Prescribe a short course (2-4 weeks on an acute script) and review at least every 3 months.
MR preparations to be prescribed by brand. Marol MR tablets are the locally preferred brand for primary care.
09.06.04
Colecalciferol
Vitamin D deficiency and insufficiency
Green (see narrative)
Formulations :
  • Tablets
Primary Care
ASPH
RSFT
SASH
SABP
Guidelines BNF SPC
R
Important
4,000iu tablets reserved for patients unable to comply with weekly dosing
09.06.04
Vitamin D deficiency and insufficiency
Green (see narrative)
Formulations :
  • Oral solution
Primary Care
ASPH
RSFT
SASH
SABP
Guidelines BNF SPC
R
Important
50,000iu/ml oral solution in ampoules - reserved for patients unable to swallow tablets / capsules
09.06.04
Vitamin D deficiency and insufficiency
Green (see narrative)
Formulations :
  • Oral drops
Primary Care
ASPH
RSFT
SASH
SABP
Guidelines BNF SPC
R
Important
10,000iu/ml oral drops sugar free - reserved for patients unable to swallow tablets / capsules
06.06.02
Denosumab
Osteoporosis
Green (see narrative)
Formulations :
  • Subcutaneous injection (sc)
Primary Care
ASPH
RSFT
SASH
SABP
BNF NICE SPC
NICE
Important
Patients with a CKD of 4 or 5 and patients with a T-score of < -4.5 to remain under specialist care.
01.07.04
02.06.01
Glyceryl trinitrate
Anal fissures
Green (see narrative)
Formulations :
  • Ointment
Primary Care
ASPH
RSFT
SASH
SABP
BNF SPC
Important
Preferred
0.4% ointment is the 1st-line treatment option in adults. Use of unlicensed strengths / formulations is not supported.
01.03.05
Lansoprazole
Acid suppression (Adults)
Green (see narrative)
Formulations :
  • Oro-dispersible
Primary Care
ASPH
RSFT
SASH
SABP
Guidelines BNF SPC
Important
Preferred
1st line in adults with swallowing difficulties. 1st line for patients with enteral feeding tubes.
01.03.05
Pantoprazole
Acid suppression (Adults)
Green (see narrative)
Formulations :
  • Tablets
Primary Care
ASPH
RSFT
SASH
SABP
Guidelines BNF SPC
Important
2nd line in adults without swallowing difficulties. (Suitable for patients that cannot have animal-derived products / capsules.)
01.03.05
Rabeprazole sodium
Acid suppression (Adults)
Green (see narrative)
Formulations :
  • Tablets
Primary Care
ASPH
RSFT
SASH
SABP
Guidelines BNF SPC
Important
2nd line in adults without swallowing difficulties. (Suitable for patients that cannot have animal-derived products / capsules.)
01.03.05
Omeprazole
Acid Suppression (Children)
Green (see narrative)
Formulations :
  • Dispersible tablets
Primary Care
ASPH
RSFT
SASH
SABP
Guidelines BNF SPC
Important
Mezzopram is the preferred brand - smaller granule size. Omeprazole MUPS is an alternative. Disperse in water then mix with juice, apple sauce or yoghurt
04.07.03
04.07.04
04.08.01
Pregabalin
Pain (Neuropathic)
Green (see narrative)
Formulations :
  • Capsules
Primary Care
ASPH
RSFT
SASH
SABP
BNF SPC
CD
SA
Important
Gabapentin is preferred due to lower potential for misuse. Pregabalin capsules more cost effective than tablets
04.06.00
Domperidone
Nausea and vomiting (pregnancy)
Green (see narrative)
Formulations :
  • Oral suspension
  • Tablets
Primary Care
ASPH
RSFT
SASH
SABP
Guidelines BNF SPC
R
SA
Un
Important
Safety alert and cardiac side-effects.
2nd line treatment option but should not be prescribed for longer than 7 days.
02.03.02
04.07.03
Lidocaine
Post herpetic neuralgia
Green (see narrative)
Formulations :
  • Medicated plaster
Primary Care
ASPH
RSFT
SASH
SABP
BNF SPC
Important
Post herpetic neuralgia only. Acute Trusts are restricted to Pain Team initiation only
04.07.04
04.08.01
Topiramate
Migraine (prevention)
Green (see narrative)
Formulations :
  • Capsules
Primary Care
ASPH
RSFT
SASH
SABP
BNF SPC
SA
Important
Pregnancy Prevention Plan required for females of childbearing potential.
Capsules (Sprinkle) reserved for use in patients who cannot swallow tablets.
04.07.04
04.08.01
Migraine (prevention)
Green (see narrative)
Formulations :
  • Oral suspension
Primary Care
ASPH
RSFT
SASH
SABP
BNF SPC
SA
Important
Pregnancy Prevention Plan required for females of childbearing potential.
Only use where patient cannot swallow tablets or capsules (sprinkle) are not suitable.
01.03.05
Omeprazole
Acid Suppression (Children)
Green (see narrative)
Formulations :
  • Dispersible tablets
Primary Care
ASPH
RSFT
SASH
SABP
Guidelines BNF SPC
04.07.02
Morphine sulfate
Pain
Green (see narrative)
Formulations :
  • Immediate release tablets
  • Oral solution
  • Oro-dispersible
Primary Care
ASPH
RSFT
SASH
SABP
Guidelines BNF SPC
CD
Important
Orodispersible tablets are a cost-effective alternative to oral solution. Reserve oral solution and orodispersible tablets for patients in whom a solid dose form is not suitable.
04.07.02
Oxycodone
Pain
Green (see narrative)
Formulations :
  • Capsules
  • Oral solution
Primary Care
ASPH
RSFT
SASH
SABP
Guidelines BNF SPC
CD
Important
For patients unable to tolerate / poor response to morphine. Modified-release preparations to be prescribed by brand
04.07.02
Tramadol hydrochloride
Pain
Green (see narrative)
Formulations :
  • Capsules
Primary Care
ASPH
RSFT
SASH
SABP
Guidelines BNF SPC
CD
Important
Consider use where maximum tolerated doses of codeine / dihydrocodeine are ineffective.
07.04.02
Solifenacin
Overactive bladder (adults)
Green (see narrative)
Formulations :
  • Oral suspension
Primary Care
ASPH
RSFT
SASH
SABP
Guidelines BNF SPC
R
Important
Only for patients with swallowing difficulties. Prescribe as solifenacin 1mg/ml oral SUSPENSION
07.04.01
Alfuzosin hydrochloride
Benign prostatic hyperplasia
Green (see narrative)
Formulations :
  • Modified release tablets
  • Tablets
Primary Care
ASPH
RSFT
SASH
SABP
BNF SPC
Important
2nd or 3rd line. Tamsulosin MR capsules or Doxazosin immediate release tablets are preferred
07.04.01
Terazosin hydrochloride
Benign prostatic hyperplasia
Green (see narrative)
Formulations :
  • Not Specified
Primary Care
ASPH
RSFT
SASH
SABP
BNF SPC
R
Important
Restricted for patients with renal or hepatic failure
01.03.05
Omeprazole
Acid Suppression (Children)
Blue
Formulations :
  • Oral suspension
Primary Care
ASPH
RSFT
SASH
SABP
Guidelines BNF SPC
04.07.02
Tapentadol hydrochloride
Pain (non-malignant)
Blue
Formulations :
  • Modified release tablets
  • Tablets
Primary Care
ASPH
RSFT
SASH
SABP
BNF SPC
CD
R
Important
Only on recommendation by a pain specialist for patients not responding to / not tolerating morphine or oxycodone
04.09.01
Selegiline hydrochloride
Parkinson's disease
Blue
Formulations :
  • Tablets
Primary Care
ASPH
RSFT
SASH
SABP
BNF NICE SPC
NICE
01.03.05
Omeprazole
Acid Suppression (Children)
Blue
Formulations :
  • Oral suspension
Primary Care
ASPH
RSFT
SASH
SABP
Guidelines BNF SPC
R
Important
Only for children under 10kg and/or with a feeding tube less than 8Fr
04.09.01
Co-beneldopa
Parkinson's disease
Blue
Formulations :
  • Capsules
  • Capsules (slow release)
  • Dispersible tablets
Primary Care
ASPH
RSFT
SASH
SABP
BNF NICE SPC
NICE
04.09.01
Ropinirole hydrochloride
Parkinson's disease
Blue
Formulations :
  • Tablets
Primary Care
ASPH
RSFT
SASH
SABP
BNF NICE SPC
NICE
04.09.01
Parkinson's disease
Blue
Formulations :
  • Modified release tablets
Primary Care
ASPH
RSFT
SASH
SABP
BNF NICE SPC
NICE
04.09.01
Pramipexole
Parkinson's disease
Blue
Formulations :
  • Tablets
Primary Care
ASPH
RSFT
SASH
SABP
BNF NICE SPC
NICE
04.09.01
Parkinson's disease
Blue
Formulations :
  • Modified release tablets
Primary Care
ASPH
RSFT
SASH
SABP
BNF NICE SPC
NICE
04.09.01
Entacapone
Parkinson's disease
Blue
Formulations :
  • Tablets
Primary Care
ASPH
RSFT
SASH
SABP
BNF NICE SPC
NICE
Important
Preferred
Preferred COMT inhibitor
04.09.01
Rotigotine
Parkinson's disease
Blue
Formulations :
  • Patches
Primary Care
ASPH
RSFT
SASH
SABP
BNF NICE SPC
NICE
Important
Consider patches if levodopa and / or oral dopamine are not effective in treating nocturnal akinesia
01.05.02
03.02.00
05.03.06
06.03.02
Budesonide
Oesophagitis (maintenance)
Blue
Formulations :
  • Oro-dispersible
Primary Care
ASPH
RSFT
SASH
SABP
BNF SPC
04.08.01
10.02.02
Cannabis (medicinal)
Spasticity and muscle spasm
Blue
Formulations :
  • Oromucosal spray
Primary Care
ASPH
RSFT
SASH
SABP
BNF SPC
CD
Important
For spasticity in MS. Specialist to prescribe for the first 12 weeks and determine response before transfer of care.
01.05.03
08.02.02
10.01.03
11.08.01
13.05.03
Ciclosporin
Dry eyes
Blue
Formulations :
  • Eye drops (unit dose)
Primary Care
ASPH
RSFT
SASH
SABP
Guidelines BNF NICE SPC
NICE
Important
0.1% ciclosporin (Ikervis). For dry eye disease that has not improved despite use of tear substitutes
Dexcom ONE (real-time continuous glucose monitoring)
Type II Diabetes (Children and Young People)
Blue
Formulations :
  • Device
Primary Care
ASPH
RSFT
SASH
SABP
BNF NICE SPC
NICE
Important
See PAD for blue information sheet
Daridorexant
Insomnia in adults
Blue
Formulations :
  • Tablets
Primary Care
ASPH
RSFT
SASH
SABP
BNF NICE SPC
NICE
FreeStyle Libre 2 (Intermittently scanned continuous glucose monitoring)
Type II Diabetes (Children and Young People)
Blue
Formulations :
  • Device
Primary Care
ASPH
RSFT
SASH
SABP
BNF NICE SPC
NICE
Important
See PAD for blue information sheet
04.09.01
Rasagiline mesilate
Parkinson's disease
Blue
Formulations :
  • Tablets
Primary Care
ASPH
RSFT
SASH
SABP
BNF SPC
04.08.01
04.08.02
Clonazepam
Parkinson's disease
Blue
Formulations :
  • Tablets
Primary Care
ASPH
RSFT
SASH
SABP
BNF SPC
Un
Important
Rapid eye movement disorder
04.01.01
Melatonin
Parkinson's disease
Blue
Formulations :
  • Modified release tablets
Primary Care
ASPH
RSFT
SASH
SABP
BNF SPC
Un
Important
Rapid eye movement disorder.
Generic 2mg MR tablets.
Testosterone (gel)
Low sexual desire in menopausal women
Blue
Formulations :
  • Not Specified
Primary Care
ASPH
RSFT
SASH
SABP
BNF SPC
Low sexual desire in menopausal women
Blue
Formulations :
  • Not Specified
Primary Care
ASPH
RSFT
SASH
SABP
BNF SPC
06.01.02
Dapagliflozin
Heart failure
Blue
Formulations :
  • Tablets
Primary Care
ASPH
RSFT
SASH
SABP
Guidelines BNF NICE SPC
NICE
06.01.02
Empagliflozin
Heart failure
Blue
Formulations :
  • Tablets
Primary Care
ASPH
RSFT
SASH
SABP
Guidelines BNF NICE SPC
NICE
04.02.01
Quetiapine
Parkinson's Disease (psychosis)
Blue
Formulations :
  • Modified release tablets
  • Tablets
Primary Care
ASPH
RSFT
SASH
SABP
BNF SPC
Un
Sildenafil
Penile rehabilitation
Blue
Formulations :
  • Tablets
Primary Care
ASPH
RSFT
SASH
SABP
BNF SPC
Rifaximin 550mg tablets
Hepatic encephalopathy
Blue
Formulations :
  • Tablets
Primary Care
ASPH
RSFT
SASH
SABP
BNF SPC
R
Important
Restricted use on recommendation of Gastroenterology consultants for treatment of hepatic encephalopathy.
02.08.02
Apixaban
Deep Vein Thrombosis (DVT) / Pulmonary Embolism (PE)
Blue
Formulations :
  • Tablets
Primary Care
ASPH
RSFT
SASH
SABP
BNF NICE SPC
NICE
Important
Specialist initiation and at least one month supply before transfer to primary care
02.08.02
Rivaroxaban
Deep Vein Thrombosis (DVT) / Pulmonary Embolism (PE)
Blue
Formulations :
  • Tablets
Primary Care
ASPH
RSFT
SASH
SABP
BNF NICE SPC
NICE
Important
Specialist initiation and at least one month supply before transfer to primary care
02.08.02
Edoxaban
Deep Vein Thrombosis (DVT) / Pulmonary Embolism (PE)
Blue
Formulations :
  • Tablets
Primary Care
ASPH
RSFT
SASH
SABP
BNF NICE SPC
NICE
Important
Specialist initiation and at least one month supply before transfer to primary care. Reserved for use where apixaban / rivaroxaban are not suitable
02.08.02
Dabigatran etexilate
Deep Vein Thrombosis (DVT) / Pulmonary Embolism (PE)
Blue
Formulations :
  • Capsules
Primary Care
ASPH
RSFT
SASH
SABP
BNF NICE SPC
NICE
Important
Specialist initiation and at least one month supply before transfer to primary care. Reserved for use where apixaban / rivaroxaban are not suitable
04.03.02
Phenelzine sulfate
Depression
Blue
Formulations :
  • Tablets
Primary Care
ASPH
RSFT
SASH
SABP
Guidelines BNF SPC
Important
Initiation and stabilisation by specialist for a minimum of 6 months before transfer of prescribing to primary care.
02.02.01
Metolazone
Heart failure
Blue
Formulations :
  • Tablets
Primary Care
ASPH
RSFT
SASH
SABP
Guidelines BNF SPC
SA
Important
Initiation by specialist. The licensed (Xaqua) and unlicensed (Zaroxolyn) tablets have different bioavailabilities. These products are not interchangable=Prescribe by Brand
06.03.02
Fludrocortisone acetate
Orthostatic hypotension
Blue
Formulations :
  • Tablets
Primary Care
ASPH
RSFT
SASH
SABP
BNF NICE SPC
Un
NICE
Important
Postural hypotension - off label use. Specialist team initiation and supply for at least 1 month before transfer of prescribing to primary care.
02.07.02
Midodrine hydrochloride
Orthostatic hypotension
Blue
Formulations :
  • Tablets
Primary Care
ASPH
RSFT
SASH
SABP
BNF SPC
Important
Postural hypotension in Parkinson's disease. Specialist team initiation and supply for at least 1 month before transfer of prescribing to primary care.
Sildenafil
Raynaud's Phenomenon
Blue
Formulations :
  • Tablets
Primary Care
ASPH
RSFT
SASH
SABP
BNF SPC
Un
Important
Transfer of prescribing to primary care only after specialist team initiation and supply of at least the first month of treatment.
02.12.00
Bempedoic acid
Lipid modification
Blue
Formulations :
  • Tablets
Primary Care
ASPH
RSFT
SASH
SABP
Guidelines BNF NICE SPC
NICE
Important
Only as add-on therapy for patients already on ezetimibe. Use the combination product (bempedoic acid with ezetimibe) in new patients. Specialist team initiation and supply of at least 3 months before transfer of prescribing to primary care.
Bempedoic acid with ezetimibe
Lipid modification
Blue
Formulations :
  • Tablets
Primary Care
ASPH
RSFT
SASH
SABP
Guidelines BNF NICE SPC
NICE
Important
Specialist team initiation and supply of at least 3 months before transfer of prescribing to primary care.
11.06.00
Timolol
Glaucoma / ocular hypertension
Blue
Formulations :
  • Eye drops
Primary Care
ASPH
RSFT
SASH
SABP
BNF SPC
Important
0.25% and 0.5% eye drops. Prescribe generically. Initiation by specialist team before transfer of prescribing to primary care.
11.06.00
Glaucoma / ocular hypertension
Blue
Formulations :
  • Eye gel
Primary Care
ASPH
RSFT
SASH
SABP
BNF SPC
Important
0.25% and 0.5% gel-forming solution (Timoptol-LA) Initiation by specialist team before transfer of prescribing to primary care.
11.06.00
Glaucoma / ocular hypertension
Blue
Formulations :
  • Eye drops (preservative free, unit dose)
Primary Care
ASPH
RSFT
SASH
SABP
BNF SPC
Important
0.1% (1mg/g) preservative free eye gel. Once daily use. Initiation by specialist team before transfer of prescribing to primary care.
06.05.01
Somatropin
Growth failure - children
Amber
Formulations :
  • Intra-articular injection
Primary Care
ASPH
RSFT
SASH
SABP
BNF NICE SPC
ICB
BlueTeq
NICE
Somatrogon
Growth failure - children
Amber
Formulations :
  • Injection
Primary Care
ASPH
RSFT
SASH
SABP
BNF NICE SPC
ICB
BlueTeq
NICE
04.04.00
Methylphenidate hydrochloride
Attention Deficit Hyperactivity Disorder (ADHD) - Adults
Amber
Formulations :
  • Modified release tablets
Primary Care
ASPH
RSFT
SASH
SABP
BNF SPC
CD
Un
Important
18mg, 27mg, 36mg, 54mg: Prescribe by brand - use the branded-generic with the lowest acquisition cost
04.04.00
Attention Deficit Hyperactivity Disorder (ADHD) - Adults
Amber
Formulations :
  • Immediate release tablets
Primary Care
ASPH
RSFT
SASH
SABP
BNF SPC
CD
Un
04.04.00
Attention Deficit Hyperactivity Disorder (ADHD) - Adults
Amber
Formulations :
  • Modified release capsules
Primary Care
ASPH
RSFT
SASH
SABP
BNF SPC
CD
Un
Sodium valproate (with childbearing potential)
Mental Health disorders
Amber
Formulations :
  • Not Specified
Primary Care
ASPH
RSFT
SASH
SABP
BNF SPC
02.03.02
Amiodarone hydrochloride
Arrhythmias
Amber
Formulations :
  • Tablets
Primary Care
ASPH
RSFT
SASH
SABP
BNF SPC
06.07.02
08.03.04
Goserelin acetate
Transgender Health - Children & Young People
Amber
Formulations :
  • Injection
Primary Care
ASPH
RSFT
SASH
SABP
Guidelines BNF SPC
Un
06.07.02
08.03.04
Leuprorelin acetate
Transgender Health - Children & Young People
Amber
Formulations :
  • Injection
Primary Care
ASPH
RSFT
SASH
SABP
Guidelines BNF SPC
Un
06.07.02
Nafarelin acetate
Transgender Health - Children & Young People
Amber
Formulations :
  • Nasal spray
Primary Care
ASPH
RSFT
SASH
SABP
Guidelines BNF SPC
Un
04.04.00
Guanfacine
Attention Deficit Hyperactivity Disorder (ADHD) - Children 6-17yrs
Amber
Formulations :
  • Modified release tablets
Primary Care
ASPH
RSFT
SASH
SABP
BNF SPC
04.04.00
Methylphenidate hydrochloride
Attention Deficit Hyperactivity Disorder (ADHD) - Children 6-17yrs
Amber
Formulations :
  • Modified release tablets
Primary Care
ASPH
RSFT
SASH
SABP
BNF SPC
CD
Important
Prescribe by brand. Xaggitin XL, Xenidate XL and Delomsart are the locally agreed brands.
04.04.00
Attention Deficit Hyperactivity Disorder (ADHD) - Children 6-17yrs
Amber
Formulations :
  • Immediate release tablets
Primary Care
ASPH
RSFT
SASH
SABP
BNF SPC
CD
Important
Prescribe immediate release tablets generically
06.04.02
Testosterone
Transgender Health - adults
Amber
Formulations :
  • Gel
  • Injection
Primary Care
ASPH
RSFT
SASH
SABP
Guidelines BNF SPC
Un
06.07.02
08.03.04
Triptorelin
Transgender Health - adults
Amber
Formulations :
  • Injection
Primary Care
ASPH
RSFT
SASH
SABP
Guidelines BNF SPC
Un
06.07.02
08.03.04
Goserelin acetate
Transgender Health - adults
Amber
Formulations :
  • Implant
Primary Care
ASPH
RSFT
SASH
SABP
Guidelines BNF SPC
Un
06.07.02
08.03.04
Leuprorelin acetate
Transgender Health - adults
Amber
Formulations :
  • Injection
Primary Care
ASPH
RSFT
SASH
SABP
Guidelines BNF SPC
Un
06.04.01
Medroxyprogesterone acetate
Transgender Health - adults
Amber
Formulations :
  • Tablets
Primary Care
ASPH
RSFT
SASH
SABP
Guidelines BNF SPC
Un
06.04.01
07.02.01
Estradiol
Transgender Health - adults
Amber
Formulations :
  • Gel
  • Patches
  • Tablets
Primary Care
ASPH
RSFT
SASH
SABP
Guidelines BNF SPC
Un
06.04.01
Ethinylestradiol
Transgender Health - adults
Amber
Formulations :
  • Tablets
Primary Care
ASPH
RSFT
SASH
SABP
Guidelines BNF SPC
Un
06.04.02
Cyproterone acetate
Transgender Health - adults
Amber
Formulations :
  • Tablets
Primary Care
ASPH
RSFT
SASH
SABP
Guidelines BNF SPC
Un
06.04.02
Finasteride
Transgender Health - adults
Amber
Formulations :
  • Tablets
Primary Care
ASPH
RSFT
SASH
SABP
Guidelines BNF SPC
Un
06.04.02
Testosterone
Transgender Health - Children & Young People
Amber
Formulations :
  • Gel
  • Injection
Primary Care
ASPH
RSFT
SASH
SABP
Guidelines BNF SPC
Un
06.07.02
08.03.04
Triptorelin
Transgender Health - Children & Young People
Amber
Formulations :
  • Injection
Primary Care
ASPH
RSFT
SASH
SABP
Guidelines BNF SPC
Un
06.04.01
07.02.01
Estradiol
Transgender Health - Children & Young People
Amber
Formulations :
  • Patches
  • Tablets
Primary Care
ASPH
RSFT
SASH
SABP
Guidelines BNF SPC
Un
10.01.03
Leflunomide
Respiratory disease indications
Amber
Formulations :
  • Tablets
Primary Care
ASPH
RSFT
SASH
SABP
BNF SPC
Un
10.01.03
Rheumatology indications
Amber
Formulations :
  • Tablets
Primary Care
ASPH
RSFT
SASH
SABP
BNF SPC
Un
04.08.01
Sodium valproate (with childbearing potential)
Epilepsy
Amber
Formulations :
  • Capsules (slow release)
  • Granules (slow release)
Primary Care
ASPH
RSFT
SASH
SABP
BNF SPC
SA
Important
Pregnancy Prevention Programme required. See MHRA advice
04.08.01
Epilepsy
Amber
Formulations :
  • Gastro-resistant tablets
  • Modified release tablets
  • Oral solution
  • Tablets
  • Crushable tablets
Primary Care
ASPH
RSFT
SASH
SABP
BNF SPC
SA
Important
Pregnancy Prevention Programme required. See MHRA advice
04.08.01
Epilepsy
Red
Formulations :
  • Injection
Primary Care
ASPH
RSFT
SASH
SABP
BNF SPC
SA
Important
Pregnancy Prevention Programme required. See MHRA advice
04.07.02
Morphine sulfate
Pain
Red
Formulations :
  • Injection
  • Solution for infusion
Primary Care
ASPH
RSFT
SASH
SABP
Guidelines BNF SPC
CD
Important
See separate listing for palliative care
04.07.02
Oxycodone
Pain
Red
Formulations :
  • Injection
Primary Care
ASPH
RSFT
SASH
SABP
Guidelines BNF SPC
CD
Important
Alternative for patients unable to tolerate / poor response to morphine. Care with dose conversion.
04.07.04
Erenumab
Migraine (prevention)
Red
Formulations :
  • Subcutaneous injection (sc)
Primary Care
ASPH
RSFT
SASH
SABP
BNF NICE SPC
ICB
BlueTeq
NICE
Preferred
04.07.04
Fremanezumab
Migraine (prevention)
Red
Formulations :
  • Subcutaneous injection (sc)
Primary Care
ASPH
RSFT
SASH
SABP
BNF NICE SPC
ICB
BlueTeq
NICE
06.07.01
Bromocriptine
Parkinson's disease
Red
Formulations :
  • Tablets
Primary Care
ASPH
RSFT
SASH
SABP
BNF SPC
SA
Important
Not a 1st-line treatment option. On-going toxicity monitoring required
04.09.01
06.07.01
Cabergoline
Parkinson's disease
Red
Formulations :
  • Tablets
Primary Care
ASPH
RSFT
SASH
SABP
BNF SPC
Important
Not a 1st-line treatment option. On-going toxicity monitoring required
04.09.01
Pergolide mesilate
Parkinson's disease
Red
Formulations :
  • Tablets
Primary Care
ASPH
RSFT
SASH
SABP
BNF SPC
Important
Not a 1st-line treatment option. On-going toxicity monitoring required
01.03.05
Omeprazole
Acid Suppression (Children)
Red
Formulations :
  • Powder
Primary Care
ASPH
RSFT
SASH
SABP
Guidelines BNF SPC
R
U
Important
Aclomep powder - ASPH NICU only
04.02.01
Clozapine
Parkinson's Disease (psychosis)
Red
Formulations :
  • Not Specified
Primary Care
ASPH
RSFT
SASH
SABP
BNF NICE SPC
SA
NICE
Important
Patient monitoring and registration required
02.03.02
10.02.02
Mexiletine hydrochloride
Myotonia
Red
Formulations :
  • Capsules
Primary Care
ASPH
RSFT
SASH
SABP
BNF NICE SPC
NHSE
BlueTeq
NICE
04.06.00
11.04.01
Dexamethasone
Diabetic macular oedema
Red
Formulations :
  • Intravitreal implant
Primary Care
ASPH
RSFT
SASH
SABP
BNF NICE SPC
ICB
BlueTeq
NICE
Important
Ophthalmology specialists only
11.04.01
Loteprednol etabonate
Postoperative pain and inflammation (eye)
Red
Formulations :
  • Eye drops
Primary Care
ASPH
RSFT
SASH
SABP
BNF SPC
Important
Max 14 day treatment - supply from the Trust
FreeStyle Libre 3 (real-time continuous glucose monitoring)
Type II Diabetes (Children and Young People)
Red
Formulations :
  • Device
Primary Care
ASPH
RSFT
SASH
SABP
BNF NICE SPC
ICB
BlueTeq
NICE
Dexcom G7 (real-time continuous glucose monitoring)
Type II Diabetes (Children and Young People)
Red
Formulations :
  • Device
Primary Care
ASPH
RSFT
SASH
SABP
BNF NICE SPC
ICB
BlueTeq
NICE
01.09.01
Chenodeoxycholic acid
Metabolic disorders
Red
Formulations :
  • Not Specified
Primary Care
ASPH
RSFT
SASH
SABP
BNF SPC
NHSE
01.03.03
Sucralfate
Gastro protection
Red
Formulations :
  • Oral suspension
  • Tablets
Primary Care
ASPH
RSFT
SASH
SABP
BNF SPC
U
01.05.03
10.01.03
13.05.02
13.05.03
Risankizumab
Psoriatic arthritis
Red
Formulations :
  • Subcutaneous injection (sc)
Primary Care
ASPH
RSFT
SASH
SABP
BNF NICE SPC
ICB
BlueTeq
NICE
10.01.03
Ustekinumab
Psoriatic arthritis
Red
Formulations :
  • Subcutaneous injection (sc)
Primary Care
ASPH
RSFT
SASH
SABP
BNF NICE SPC
ICB
BlueTeq
NICE
10.01.03
Sarilumab
Rheumatoid arthritis
Red
Formulations :
  • Subcutaneous injection (sc)
Primary Care
ASPH
RSFT
SASH
SABP
BNF NICE SPC
ICB
BlueTeq
NICE
Important
Severe disease only
01.05.03
10.01.03
Tofacitinib
Rheumatoid arthritis
Red
Formulations :
  • Tablets
Primary Care
ASPH
RSFT
SASH
SABP
BNF NICE SPC
SA
ICB
BlueTeq
NICE
Important
Severe disease only
13.05.03
Tralokinumab
Atopic dermatitis
Red
Formulations :
  • Subcutaneous injection (sc)
Primary Care
ASPH
RSFT
SASH
SABP
Guidelines BNF NICE SPC
SA
ICB
BlueTeq
NICE
01.05.03
10.01.03
13.05.03
Upadacitinib
Atopic dermatitis
Red
Formulations :
  • Tablets
Primary Care
ASPH
RSFT
SASH
SABP
Guidelines BNF NICE SPC
SA
ICB
BlueTeq
NICE
10.01.03
13.05.03
Baricitinib
Atopic dermatitis
Red
Formulations :
  • Tablets
Primary Care
ASPH
RSFT
SASH
SABP
Guidelines BNF NICE SPC
SA
ICB
BlueTeq
NICE
01.05.03
10.01.03
13.05.02
13.05.03
Risankizumab
Inflammatory bowel disease
Red
Formulations :
  • Subcutaneous injection (sc)
  • Intravenous infusion
Primary Care
ASPH
RSFT
SASH
SABP
Guidelines BNF NICE SPC
ICB
BlueTeq
NICE
Important
For UC & CD. Adults only
Continuous Glucose Monitoring
Congenital hyperinsulinism
Red
Formulations :
  • Device
Primary Care
ASPH
RSFT
SASH
SABP
BNF SPC
ICB
BlueTeq
09.06.04
Colecalciferol
Vitamin D deficiency and insufficiency
Red
Formulations :
  • Tablets
Primary Care
ASPH
RSFT
SASH
SABP
Guidelines BNF SPC
R
Important
25,000iu tablets
04.07.04
Rimegepant
Migraine (prevention)
Red
Formulations :
  • Oral lyophilisates
Primary Care
ASPH
RSFT
SASH
SABP
BNF NICE SPC
ICB
BlueTeq
NICE
Important
For episodic migraine only
Deucravacitinib
Psoriasis
Red
Formulations :
  • Tablets
Primary Care
ASPH
RSFT
SASH
SABP
Guidelines BNF NICE SPC
SA
ICB
BlueTeq
NICE
06.02.01
Liothyronine sodium
Treatment resistant depression
Red
Formulations :
  • Capsules
  • Tablets
Primary Care
ASPH
RSFT
SASH
SABP
BNF SPC
R
Un
Important
Consultant psychiatrists only.
06.01.02
Semaglutide
Weight management in adults
Red
Formulations :
  • Pre-filled pen
  • Subcutaneous injection (sc)
Primary Care
ASPH
RSFT
SASH
SABP
Guidelines BNF NICE SPC
R
NICE
13.05.02
13.05.03
Tildrakizumab
Psoriasis
Red
Formulations :
  • Not Specified
Primary Care
ASPH
RSFT
SASH
SABP
Guidelines BNF NICE SPC
ICB
BlueTeq
NICE
Bimekizumab
Psoriasis
Red
Formulations :
  • Not Specified
Primary Care
ASPH
RSFT
SASH
SABP
Guidelines BNF SPC
04.06.00
Domperidone
Parkinson's Disease (apomorphine pre-treatment)
Red
Formulations :
  • Tablets
Primary Care
ASPH
RSFT
SASH
SABP
BNF SPC
Un
04.08.01
Cenobamate
Epilepsy
Red
Formulations :
  • Tablets
Primary Care
ASPH
RSFT
SASH
SABP
BNF SPC
Important
For initiation by tertiary centres only
Insulin pump - Type 1 diabetes
Diabetes Mellitus
Red
Formulations :
  • Not Specified
Primary Care
ASPH
RSFT
SASH
SABP
Guidelines BNF SPC
06.01.02
Liraglutide
Weight management in adults
Red
Formulations :
  • Subcutaneous injection (sc)
Primary Care
ASPH
RSFT
SASH
SABP
Guidelines BNF SPC
04.06.00
Domperidone
Lactation stimulation
Red
Formulations :
  • Tablets
Primary Care
ASPH
RSFT
SASH
SABP
BNF SPC
SA
Un
10.03.02
Capsaicin
Pain (Neuropathic)
Red
Formulations :
  • Patches
Primary Care
ASPH
RSFT
SASH
SABP
BNF SPC
R
Important
For patients with localised neuropathic pain who cannot tolerate / wish to avoid oral treatments (amitriptyline or duloxetine)
To be initiated by specialist pain care teams only
Remdesivir
Covid-19
Red
Formulations :
  • Intravenous infusion
Primary Care
ASPH
RSFT
SASH
SABP
BNF NICE SPC
NICE
Sotrovimab
Covid-19
Red
Formulations :
  • Not Specified
Primary Care
ASPH
RSFT
SASH
SABP
BNF SPC
02.03.02
Dronedarone hydrochloride
Atrial fibrillation
Red
Formulations :
  • Tablets
Primary Care
ASPH
RSFT
SASH
SABP
Guidelines BNF SPC
Important
Cardiology only
02.03.02
Amiodarone hydrochloride
Arrhythmias
Red
Formulations :
  • Injection
Primary Care
ASPH
RSFT
SASH
SABP
BNF SPC
Andexanet alfa
Anticoagulation reversal
Red
Formulations :
  • Infusion
Primary Care
ASPH
RSFT
SASH
SABP
BNF NICE SPC
NICE
Important
Apixaban / rivaroxaban anticoagulant reversal. RESTRICTED to Haematologists only
04.07.02
Tramadol hydrochloride
Pain
Red
Formulations :
  • Injection
Primary Care
ASPH
RSFT
SASH
SABP
Guidelines BNF SPC
CD
01.05.02
03.02.00
05.03.06
06.03.02
Budesonide
Oesophagitis (inducing remission)
Red
Formulations :
  • Oro-dispersible
Primary Care
ASPH
RSFT
SASH
SABP
BNF SPC
04.06.00
Domperidone
Gastric reflux in Neonates and Children
Red
Formulations :
  • Oral suspension
  • Tablets
Primary Care
ASPH
RSFT
SASH
SABP
BNF SPC
Un
Important
Refer to MHRA cardiac safety alerts. Off label use.
Minocycline
Non-acne dermatological indications
Red
Formulations :
  • Modified release tablets
  • Tablets
Primary Care
ASPH
RSFT
SASH
SABP
BNF SPC
R
Important
Restricted Use - for use when indicated by local trust antimicrobial guidelines or specialist microbiology recommendation.
02.03.02
10.02.02
Mexiletine hydrochloride
Arrhythmias
Red
Formulations :
  • Capsules
Primary Care
ASPH
RSFT
SASH
SABP
BNF SPC
Important
Namuscla brand is non-preferred for this indication
Aflibercept
Diabetic macular oedema
Red
Formulations :
  • Not Specified
Primary Care
ASPH
RSFT
SASH
SABP
BNF NICE SPC
ICB
BlueTeq
NICE
11.08.02
Ranibizumab
Retinal Vein Occlusion
Red
Formulations :
  • Intravitreal injection
Primary Care
ASPH
RSFT
SASH
SABP
Guidelines BNF NICE SPC
ICB
BlueTeq
NICE
11.08.02
Diabetic macular oedema
Red
Formulations :
  • Intravitreal injection
Primary Care
ASPH
RSFT
SASH
SABP
BNF NICE SPC
ICB
BlueTeq
NICE
11.08.02
Wet age-related macular degeneration
Red
Formulations :
  • Intravitreal injection
Primary Care
ASPH
RSFT
SASH
SABP
BNF NICE SPC
ICB
BlueTeq
NICE
11.08.02
Myopic choroidal neovascularisation
Red
Formulations :
  • Intravitreal injection
Primary Care
ASPH
RSFT
SASH
SABP
BNF NICE SPC
ICB
BlueTeq
NICE
Fostamatinib
Immune thrombocytopenia
Red
Formulations :
  • Not Specified
Primary Care
ASPH
RSFT
SASH
SABP
BNF SPC
03.07.00
Tezacaftor with ivacaftor
Cystic fibrosis
Red
Formulations :
  • Not Specified
Primary Care
ASPH
RSFT
SASH
SABP
BNF SPC
Important
NHSE Specialist Commissioned Services only
Nicotine 450 micrograms dose/inhaler
Smoking cessation
N/A
Formulations :
  • Not Specified
Primary Care
ASPH
RSFT
SASH
SABP
BNF SPC
Somatrogon
Growth failure - children
N/A
Formulations :
  • Not Specified
Primary Care
ASPH
RSFT
SASH
SABP
BNF SPC
Guidelines
Inflammatory bowel disease
N/A
Formulations :
  • Not Specified
Primary Care
ASPH
RSFT
SASH
SABP
Guidelines BNF SPC
Inflammatory bowel disease
N/A
Formulations :
  • Not Specified
Primary Care
ASPH
RSFT
SASH
SABP
Guidelines BNF SPC
Oscillating Positive Expiratory Pressure Device
Mucous clearance
N/A
Formulations :
  • Device
Primary Care
ASPH
RSFT
SASH
SABP
BNF SPC
06.04.02
Testosterone
Low sexual desire in menopausal women
Non Formulary
Formulations :
  • Cream
Primary Care
ASPH
RSFT
SASH
SABP
BNF SPC
U
Important
Androfeme is unlicensed in the UK. Other products can be used off-label
01.07.04
02.06.01
Glyceryl trinitrate
Anal fissures
Non Formulary
Formulations :
  • Cream
  • Ointment
Primary Care
ASPH
RSFT
SASH
SABP
BNF SPC
NFD1
U
Important
0.4% ointment is the 1st-line treatment option in adults. 0.1%, 0.2% and 2% creams and ointments are non-formulary
01.05.02
11.04.01
Prednisolone
Inflammatory bowel disease
Non Formulary
Formulations :
  • Foam enema
Primary Care
ASPH
RSFT
SASH
SABP
Guidelines BNF SPC
NFD1
Important
Budesonide rectal foam is preferred. Steroid safety considerations
03.04.01
Alimemazine tartrate
Sleep disorders in children and adolescents
Non Formulary
Formulations :
  • Not Specified
Primary Care
ASPH
RSFT
SASH
SABP
BNF SPC
NFD1
Un
GlucoRx Aidex (real-time continuous glucose monitoring)
Type II Diabetes (Children and Young People)
Non Formulary
Formulations :
  • Device
Primary Care
ASPH
RSFT
SASH
SABP
BNF NICE SPC
NICE
Glucomen Day (real-time continuous glucose monitoring)
Type II Diabetes (Children and Young People)
Non Formulary
Formulations :
  • Device
Primary Care
ASPH
RSFT
SASH
SABP
BNF NICE SPC
NICE
A8 Touchcare Nano (real-time continuous glucose monitoring)
Type II Diabetes (Children and Young People)
Non Formulary
Formulations :
  • Device
Primary Care
ASPH
RSFT
SASH
SABP
BNF NICE SPC
NICE
Dexcom G6 (real-time continuous glucose monitoring)
Type II Diabetes (Children and Young People)
Non Formulary
Formulations :
  • Device
Primary Care
ASPH
RSFT
SASH
SABP
BNF NICE SPC
NICE
Medtronic Guardian (real-time continuous glucose monitoring)
Type II Diabetes (Children and Young People)
Non Formulary
Formulations :
  • Device
Primary Care
ASPH
RSFT
SASH
SABP
BNF NICE SPC
NICE
04.07.03
Nortriptyline
Pain (Neuropathic)
Non Formulary
Formulations :
  • Not Specified
Primary Care
ASPH
RSFT
SASH
SABP
BNF SPC
NFD1
04.01.01
Melatonin
Jet lag disorder
Non Formulary
Formulations :
  • Not Specified
Primary Care
ASPH
RSFT
SASH
SABP
BNF SPC
NFD1
04.02.01
04.06.00
Olanzapine
Parkinson's Disease (psychosis)
Non Formulary
Formulations :
  • Not Specified
Primary Care
ASPH
RSFT
SASH
SABP
BNF SPC
NFD1
01.03.05
Omeprazole
Acid Suppression (Children)
Non Formulary
Formulations :
  • Tablets
Primary Care
ASPH
RSFT
SASH
SABP
Guidelines BNF SPC
NFD1
01.03.05
Lansoprazole
Acid suppression (Adults)
Non Formulary
Formulations :
  • Liquid
  • Oral solution
  • Oral suspension
Primary Care
ASPH
RSFT
SASH
SABP
Guidelines BNF SPC
Important
Lansoprazole oro-dispersible tablets are 1st-line for adults with swallowing dificulties or enteral feeding tubes.
01.03.05
Omeprazole
Acid suppression (Adults)
Non Formulary
Formulations :
  • Tablets
Primary Care
ASPH
RSFT
SASH
SABP
Guidelines BNF SPC
NFD1
Important
Omeprazole or lansoprazole capsules are 1st-line. Pantoprazole or rabeprazole tablets are 2nd-line for patients without swallowing difficulties (suitable for patients that cannot have animal-derived products).
01.03.05
Acid suppression (Adults)
Non Formulary
Formulations :
  • Oral suspension
  • Oro-dispersible
Primary Care
ASPH
RSFT
SASH
SABP
Guidelines BNF SPC
NFD1
Important
Omeprazole capsules can be opened for patients with swallowing difficulties. Lansoprazole oro-dispersible tablets are 1st-line for patients with enteral feeding tubes
04.09.01
Co-beneldopa
Parkinson's disease (challenge test)
Non Formulary
Formulations :
  • Not Specified
Primary Care
ASPH
RSFT
SASH
SABP
BNF SPC
NFD1
04.09.01
Co-careldopa
Parkinson's disease (challenge test)
Non Formulary
Formulations :
  • Not Specified
Primary Care
ASPH
RSFT
SASH
SABP
BNF SPC
NFD1
04.09.01
Apomorphine hydrochloride
Parkinson's disease (challenge test)
Non Formulary
Formulations :
  • Not Specified
Primary Care
ASPH
RSFT
SASH
SABP
BNF SPC
NFD1
04.09.01
Ropinirole hydrochloride
Parkinson's disease (neuroprotective therapy)
Non Formulary
Formulations :
  • Not Specified
Primary Care
ASPH
RSFT
SASH
SABP
BNF SPC
NFD1
04.09.01
Pramipexole
Parkinson's disease (neuroprotective therapy)
Non Formulary
Formulations :
  • Not Specified
Primary Care
ASPH
RSFT
SASH
SABP
BNF SPC
NFD1
04.09.01
Rasagiline
Parkinson's disease (neuroprotective therapy)
Non Formulary
Formulations :
  • Not Specified
Primary Care
ASPH
RSFT
SASH
SABP
BNF SPC
NFD1
04.09.01
Selegiline hydrochloride
Parkinson's disease (neuroprotective therapy)
Non Formulary
Formulations :
  • Not Specified
Primary Care
ASPH
RSFT
SASH
SABP
BNF SPC
NFD1
04.09.02
Orphenadrine hydrochloride
Parkinson's disease
Non Formulary
Formulations :
  • Not Specified
Primary Care
ASPH
RSFT
SASH
SABP
BNF SPC
NFD1
04.09.02
Procyclidine hydrochloride
Parkinson's disease
Non Formulary
Formulations :
  • Not Specified
Primary Care
ASPH
RSFT
SASH
SABP
BNF SPC
NFD1
04.09.02
Trihexyphenidyl hydrochloride
Parkinson's disease
Non Formulary
Formulations :
  • Not Specified
Primary Care
ASPH
RSFT
SASH
SABP
BNF SPC
NFD1
04.07.03
04.07.04
04.08.01
Gabapentin
Migraine (prevention)
Non Formulary
Formulations :
  • Not Specified
Primary Care
ASPH
RSFT
SASH
SABP
BNF NICE SPC
NFD1
NICE
04.07.03
04.07.04
04.08.01
Pregabalin
Migraine (prevention)
Non Formulary
Formulations :
  • Not Specified
Primary Care
ASPH
RSFT
SASH
SABP
BNF SPC
NFD1
07.04.02
Solifenacin
Overactive bladder (adults)
Non Formulary
Formulations :
  • Oral solution
Primary Care
ASPH
RSFT
SASH
SABP
Guidelines BNF SPC
NFD1
Important
Prescribe as solifenacin 1mg/ml oral SUSPENSION
07.04.02
Tamsulosin hydrochloride
Benign prostatic hyperplasia
Non Formulary
Formulations :
  • Modified release tablets
Primary Care
ASPH
RSFT
SASH
SABP
BNF SPC
NFD1
Important
Use modified release capsules
07.04.01
Doxazosin
Benign prostatic hyperplasia
Non Formulary
Formulations :
  • Modified release tablets
Primary Care
ASPH
RSFT
SASH
SABP
BNF SPC
NFD1
Important
Use immediate release tablets
07.04.01
07.04.05
Avanafil
Benign prostatic hyperplasia
Non Formulary
Formulations :
  • Not Specified
Primary Care
ASPH
RSFT
SASH
SABP
BNF SPC
NFD1
07.04.01
Indoramin
Benign prostatic hyperplasia
Non Formulary
Formulations :
  • Not Specified
Primary Care
ASPH
RSFT
SASH
SABP
BNF SPC
NFD1
02.05.04
07.04.01
Prazosin hydrochloride
Benign prostatic hyperplasia
Non Formulary
Formulations :
  • Not Specified
Primary Care
ASPH
RSFT
SASH
SABP
BNF SPC
NFD1
07.04.01
Sildenafil
Benign prostatic hyperplasia
Non Formulary
Formulations :
  • Not Specified
Primary Care
ASPH
RSFT
SASH
SABP
BNF SPC
NFD1
07.04.01
07.04.05
Vardenafil
Benign prostatic hyperplasia
Non Formulary
Formulations :
  • Not Specified
Primary Care
ASPH
RSFT
SASH
SABP
BNF SPC
NFD1
04.06.00
Betahistine hydrochloride
Tinnitus
Non Formulary
Formulations :
  • Not Specified
Primary Care
ASPH
RSFT
SASH
SABP
BNF SPC
04.07.03
07.04.02
Imipramine hydrochloride
Overactive bladder (adults)
Non Formulary
Formulations :
  • Not Specified
Primary Care
ASPH
RSFT
SASH
SABP
Guidelines BNF SPC
Minocycline
Acne
Non Formulary
Formulations :
  • Not Specified
Primary Care
ASPH
RSFT
SASH
SABP
Guidelines BNF SPC
Bezlotuxumab
Clostridioides difficile
Non Formulary
Formulations :
  • Not Specified
Primary Care
ASPH
RSFT
SASH
SABP
BNF SPC
NFD1
Important
The Surrey Heartlands integrated care system Area Prescribing Committee (APC) agreed with NICE recommendation not to use bezlotoxumab to prevent recurrence of C. Difficile infection because it is not cost effective. Bezlotoxumab will be given a NON-FORMULARY traffic light status for this indication.
Minocycline
Acne
Non Formulary
Formulations :
  • Not Specified
Primary Care
ASPH
RSFT
SASH
SABP
Guidelines BNF SPC
01.05.01
Balsalazide sodium
Inflammatory bowel disease
Non Formulary
Formulations :
  • Not Specified
Primary Care
ASPH
RSFT
SASH
SABP
Guidelines BNF SPC
02.05.05
Azilsartan medoxomil
Hypertension
Non Formulary
Formulations :
  • Not Specified
Primary Care
ASPH
RSFT
SASH
SABP
Guidelines BNF SPC
NFD1
02.05.05
Eprosartan
Hypertension
Non Formulary
Formulations :
  • Not Specified
Primary Care
ASPH
RSFT
SASH
SABP
Guidelines BNF SPC
NFD1
02.02.01
Metolazone
Hypertension
Non Formulary
Formulations :
  • Tablets
Primary Care
ASPH
RSFT
SASH
SABP
Guidelines BNF SPC
NFD1
01.05.02
11.04.01
Prednisolone
Inflammatory bowel disease
Non Formulary
Formulations :
  • Gastro-resistant tablets
Primary Care
ASPH
RSFT
SASH
SABP
Guidelines BNF SPC
Important
Enteric coated tablets - non-formulary
04.07.02
Tramadol with Dexketoprofen
Pain
Non Formulary
Formulations :
  • Not Specified
Primary Care
ASPH
RSFT
SASH
SABP
Guidelines BNF SPC
04.07.02
Morphine sulfate
Pain
Non Formulary
Formulations :
  • Suppositories
Primary Care
ASPH
RSFT
SASH
SABP
Guidelines BNF SPC
CD
04.07.02
Tramadol hydrochloride
Pain
Non Formulary
Formulations :
  • Oral solution
Primary Care
ASPH
RSFT
SASH
SABP
Guidelines BNF SPC
CD
04.07.02
Pain
Non Formulary
Formulations :
  • Oral drops
Primary Care
ASPH
RSFT
SASH
SABP
Guidelines BNF SPC
CD
07.04.01
07.04.05
Vardenafil
Penile rehabilitation
Non Formulary
Formulations :
  • Not Specified
Primary Care
ASPH
RSFT
SASH
SABP
BNF SPC
NFD1
01.03.05
Esomeprazole
Acid suppression (Adults)
Non Formulary
Formulations :
  • Tablets
Primary Care
ASPH
RSFT
SASH
SABP
Guidelines BNF SPC
02.12.00
Nicotinic acid
Familial hypercholesterolaemia
Non Formulary
Formulations :
  • Not Specified
Primary Care
ASPH
RSFT
SASH
SABP
BNF SPC
NFD1
02.12.00
Gemfibrozil
Lipid modification
Non Formulary
Formulations :
  • Capsules
  • Tablets
Primary Care
ASPH
RSFT
SASH
SABP
Guidelines BNF SPC
NFD1
Important
Not for initiation in new patients.
09.01.01
Ferric maltol
Iron-deficiency anaemia
See Below
Formulations :
  • Not Specified
Primary Care
ASPH
RSFT
SASH
SABP
BNF SPC
HRT continuous combined
Menopausal disorders
See Below
Formulations :
  • Not Specified
Primary Care
ASPH
RSFT
SASH
SABP
Guidelines BNF SPC
05.03.06
Molnupiravir
Covid-19
See narrative
Formulations :
  • Not Specified
Primary Care
ASPH
RSFT
SASH
SABP
BNF SPC
05.03.06
Covid-19
See narrative
Formulations :
  • Not Specified
Primary Care
ASPH
RSFT
SASH
SABP
BNF SPC
01.05.02
03.02.00
05.03.06
06.03.02
Budesonide
Covid-19
See narrative
Formulations :
  • Not Specified
Primary Care
ASPH
RSFT
SASH
SABP
BNF SPC
Minocycline
Acne
See narrative
Formulations :
  • Not Specified
Primary Care
ASPH
RSFT
SASH
SABP
Guidelines BNF SPC
This site uses its own and third party cookies to function properly and to improve performance, to maintain the session and to personalise user experience, as well as to obtain anonymous statistics about the use of the website. Visit our Privacy and Cookie Policy for more information on our data collection practices. By clicking 'Accept' you agree to our use of cookies for the purposes listed.
 Learn More